JP2006508692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508692A5 JP2006508692A5 JP2005502022A JP2005502022A JP2006508692A5 JP 2006508692 A5 JP2006508692 A5 JP 2006508692A5 JP 2005502022 A JP2005502022 A JP 2005502022A JP 2005502022 A JP2005502022 A JP 2005502022A JP 2006508692 A5 JP2006508692 A5 JP 2006508692A5
- Authority
- JP
- Japan
- Prior art keywords
- mononuclear cells
- hematopoietic
- nicotinamide
- conditions
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000005087 mononuclear cell Anatomy 0.000 claims 64
- 238000000034 method Methods 0.000 claims 36
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 35
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical class NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 32
- 230000003394 haemopoietic effect Effects 0.000 claims 32
- 230000000694 effects Effects 0.000 claims 28
- 239000003795 chemical substances by application Substances 0.000 claims 24
- 150000005480 nicotinamides Chemical class 0.000 claims 20
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 19
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 19
- 238000012258 culturing Methods 0.000 claims 17
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 16
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 16
- 239000011570 nicotinamide Chemical class 0.000 claims 16
- 235000005152 nicotinamide Nutrition 0.000 claims 16
- 229960003966 nicotinamide Drugs 0.000 claims 16
- 230000004069 differentiation Effects 0.000 claims 13
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 239000013522 chelant Substances 0.000 claims 9
- 239000002738 chelating agent Substances 0.000 claims 9
- 102000009310 vitamin D receptors Human genes 0.000 claims 9
- 108050000156 vitamin D receptors Proteins 0.000 claims 9
- 239000002207 metabolite Substances 0.000 claims 8
- 229960001727 tretinoin Drugs 0.000 claims 8
- 239000011710 vitamin D Substances 0.000 claims 8
- 229940046008 vitamin d Drugs 0.000 claims 8
- 102000004127 Cytokines Human genes 0.000 claims 7
- 108090000695 Cytokines Proteins 0.000 claims 7
- 102000034527 Retinoid X Receptors Human genes 0.000 claims 6
- 108010038912 Retinoid X Receptors Proteins 0.000 claims 6
- 229930003316 Vitamin D Natural products 0.000 claims 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 229930002330 retinoic acid Natural products 0.000 claims 6
- 102000003702 retinoic acid receptors Human genes 0.000 claims 6
- 108090000064 retinoic acid receptors Proteins 0.000 claims 6
- 235000019166 vitamin D Nutrition 0.000 claims 6
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 5
- 229910052802 copper Inorganic materials 0.000 claims 5
- 239000010949 copper Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- -1 nicotinamide, nicotinamide analog Chemical class 0.000 claims 5
- 230000019491 signal transduction Effects 0.000 claims 5
- 238000003556 assay Methods 0.000 claims 4
- 230000004663 cell proliferation Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000011124 ex vivo culture Methods 0.000 claims 4
- 230000002452 interceptive effect Effects 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 229910052723 transition metal Inorganic materials 0.000 claims 4
- 150000003624 transition metals Chemical class 0.000 claims 4
- 229940122756 Retinoic acid receptor antagonist Drugs 0.000 claims 3
- 229940116327 Retinoid X receptor antagonist Drugs 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108091027757 Deoxyribozyme Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical group N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000003167 anti-vitamin Effects 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims 2
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000646 Interleukin-3 Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 108700014844 flt3 ligand Proteins 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 229940076264 interleukin-3 Drugs 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 claims 1
- HFZXBZIYMINYKS-UHFFFAOYSA-N n-sulfanylpyridine-3-carboxamide Chemical compound SNC(=O)C1=CC=CN=C1 HFZXBZIYMINYKS-UHFFFAOYSA-N 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40413702P | 2002-08-19 | 2002-08-19 | |
| US40414502P | 2002-08-19 | 2002-08-19 | |
| IL15290402A IL152904A0 (en) | 2002-01-24 | 2002-11-17 | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| PCT/IL2003/000062 WO2003062404A1 (en) | 2002-01-25 | 2003-01-23 | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
| PCT/IL2003/000064 WO2003062369A2 (en) | 2002-01-24 | 2003-01-26 | Expansion of renewable stem cell populations |
| US45254503P | 2003-03-07 | 2003-03-07 | |
| PCT/IL2003/000681 WO2004016731A2 (en) | 2002-08-19 | 2003-08-17 | Ex-vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508692A JP2006508692A (ja) | 2006-03-16 |
| JP2006508692A5 true JP2006508692A5 (enExample) | 2006-07-13 |
Family
ID=56290470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005502022A Pending JP2006508692A (ja) | 2002-08-19 | 2003-08-17 | 単核細胞培養物における造血幹細胞集団のエクスビボ拡大 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1534820A4 (enExample) |
| JP (1) | JP2006508692A (enExample) |
| AU (1) | AU2003250519A1 (enExample) |
| BR (1) | BR0314402A (enExample) |
| CA (1) | CA2495824A1 (enExample) |
| MX (1) | MXPA05001992A (enExample) |
| WO (1) | WO2004016731A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU770896C (en) | 1998-09-29 | 2006-09-07 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
| IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| WO2003062404A1 (en) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
| AU2004217699B2 (en) * | 2003-03-07 | 2008-07-03 | Gamida-Cell Ltd. | Expansion of renewable stem cell populations using modulators of PI 3-kinase |
| US8361976B2 (en) | 2004-07-09 | 2013-01-29 | University Of Massachusetts | Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules |
| EP2390312A1 (en) * | 2005-11-29 | 2011-11-30 | Gamida Cell Ltd. | Methods of improving stem cell homing and engraftment |
| US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| US8263403B2 (en) | 2007-04-23 | 2012-09-11 | Stowers Institute For Medical Research | Methods and compositions for stem cell self-renewal |
| DK2250251T3 (en) | 2008-01-09 | 2018-01-22 | Sartorius Stedim Cellca Gmbh | Improved culture medium additive and method of using it |
| US20150064273A1 (en) | 2012-02-13 | 2015-03-05 | Gamida-Cell Ltd. | Mesenchymal Stem Cells Conditioned Medium and Methods of Generating and Using the Same |
| US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| CA3036926C (en) * | 2016-09-30 | 2022-05-31 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050220774A1 (en) * | 2002-03-18 | 2005-10-06 | Tony Peled | Methods of inducing differentiation in ex vivo expanded stem cells |
-
2003
- 2003-08-17 WO PCT/IL2003/000681 patent/WO2004016731A2/en not_active Ceased
- 2003-08-17 BR BR0314402-0A patent/BR0314402A/pt not_active Application Discontinuation
- 2003-08-17 MX MXPA05001992A patent/MXPA05001992A/es active IP Right Grant
- 2003-08-17 JP JP2005502022A patent/JP2006508692A/ja active Pending
- 2003-08-17 CA CA002495824A patent/CA2495824A1/en not_active Abandoned
- 2003-08-17 AU AU2003250519A patent/AU2003250519A1/en not_active Abandoned
- 2003-08-17 EP EP03787995A patent/EP1534820A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508692A5 (enExample) | ||
| Mayani et al. | Cytokine-induced selective expansion and maturation of erythroid versus myeloid progenitors from purified cord blood precursor cells | |
| US5646043A (en) | Methods for the ex vivo replication of human stem cells and/or expansion of human progenitor cells | |
| US6667034B2 (en) | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture, methods for assaying the effect of substances on lineage-specific cell production, and cell compositions produced by these cultures | |
| Neumann et al. | Production of a macrophage growth factor (s) by a goldfish macrophage cell line and macrophages derived from goldfish kidney leukocytes | |
| Reems et al. | Cell cycle and functional differences between CD34+/CD38hi and CD34+/38lo human marrow cells after in vitro cytokine exposure | |
| CN106414722B (zh) | 红系细胞的体外扩增 | |
| EP1551953A2 (en) | Modulation of stem and progenitor cell differentiation, assays, and uses thereof | |
| CN107828727A (zh) | 产生自然杀伤细胞的方法、由此获得的细胞群体及其用途 | |
| CN105705021A (zh) | 用于治疗血液病症的富集和扩增的人脐带血干细胞 | |
| US11702635B2 (en) | Hematopoietic stem cell expansion method | |
| Zandstra et al. | Cellular determinants affecting the rate of cytokine in cultures of human hematopoietic cells | |
| CN111117958B (zh) | 一种人外周血调节性t细胞的体外扩增试剂盒及扩增方法 | |
| JP2016530895A (ja) | 動物細胞を遺伝子改変する改良された方法 | |
| Boehm et al. | The potential of human peripheral blood derived CD34+ cells for ex vivo red blood cell production | |
| Alcorn et al. | Ex vivo expansion of haemopoietic progenitor cells | |
| JP2009517078A5 (enExample) | ||
| Pilipow et al. | Generating stem-like memory T cells with antioxidants for adoptive cell transfer immunotherapy of cancer | |
| Chen et al. | Pharmacological inhibition of AKT activity in human CD34+ cells enhances their ability to engraft immunodeficient mice | |
| EP4587556A1 (en) | Method of differentiation of pluripotent stem cells to hematopoietic precursor and stem cells | |
| McAdams et al. | Ex vivo expansion of primitive hematopoietic cells for cellular therapies: An overview | |
| CN116574680A (zh) | 一种体外高效扩增nk细胞的培养基和培养方法 | |
| Leung et al. | Cytokines in the differentiation therapy of leukemia: from laboratory investigations to clinical applications | |
| Olesen et al. | Long-term culture of hematopoietic stem cells-validating the stromal component of the CAFC assay | |
| CN118726252B (zh) | 免疫细胞培养基和免疫细胞的培养方法 |